← Back to Patent Explorer
US4808533A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of preventing T-cell blastogenesis

Assignee: Shanksville Corp NV
•
Filing: 1985-05-03
•
Granted: 1989-02-28
•
Expires: 2005-05-03
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free and mitogen-free interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth. Inhibitors for the formation of T-cell blasts in cell mediated immunological response provide a powerful new tool for preventing host-graft rejection. These inhibitors are alkylating agents for serine esterase enzymes which have been found to be involved in the cell mediated immunological response system which generates natural Killer (NK) cells, the latter being responsible for graft rejection in a host.

Inventors

  • 👤 Hans-Ake Fabricius
  • 👤 Eckart U. Kottgen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 00:12
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 33 words
A method for preventing T-cell blast formation comprising adding a serine esterase enzyme inhibiting alkylating agent to a system containing Interleukin-1, T-cell growth factor, and peripheral blood T-cell lymphocytes, thereby preventing T-cell blastogenesis.
Claim 2
Independent Claim 33 words
A method for preventing T-cell blast formation comprising adding a serine esterase enzyme inhibiting alkylating agent to a system containing Interleukin-1, T-cell growth factor, and peripheral blood T-cell lymphocytes, thereby preventing T-cell blastogenesis.
Claim 3
Dependent Claim 21 words
The method of claim 1 wherein said alkylating agent is selected from the group consisting of diisopropylfluorophosphate and phenylmethyl sulfonic fluoride.

References Cited (Backward Citations)

US4406830A Cited
US4661447A Cited
US4681844A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-02-28 1992-08-29 1993-02-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-02-28 1996-08-29 1997-02-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-02-28 2000-08-29 2001-02-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag